HCRTR1
Orexin/Hypocretin receptor type 1
As of the edition of 20 October 2026, HCRTR1 (orexin/Hypocretin receptor type 1, UniProt O43613) has 9 drugs tested at it and 8 companies on the list, 2 on route A and 4 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O43613
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 14
- Disease areas
- Mental health; Nervous system; Chemically induced; Lungs and airways; Digestive system; Nutrition and metabolism; Cancer; Hormones
- Registered trials of its drugs
- 182
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Went quiet | 4 |
| Stopped | 1 |
| Total | 9 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Suvorexant | Marketed | Phase 4 | Ends 2029 |
| Lemborexant | Marketed | Phase 4 | Ends 2031 |
| Daridorexant | Marketed | Phase 4 | Ends 2034 |
| Orn-0829 hydrate | Marketed | Phase 3 | none listed |
| Almorexant | Went quiet | Phase 3 | none listed |
| SB-649868 | Went quiet | Phase 2 | none listed |
| Filorexant | Stopped | Phase 2 | none listed |
| ACT-462206 | Went quiet | Phase 1 | none listed |
| LEM10 | Went quiet | Phase 1 | none listed |
9 of 9 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 4 |
| Undetermined | 2 |
| Total on the list | 8 |
| Company | Route |
|---|---|
| Idorsia Pharmaceuticals | Route B |
| Merck & Co. | Route B |
| Eisai | Route B |
The other 5 companies at HCRTR1
In the product8 companies in all; 5 are not named here, and no score is.
See the 8 companies at HCRTR1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.